<SUBMISSION>
<ACCESSION-NUMBER>0001047469-05-027119
<TYPE>SC 14D9/A
<PUBLIC-DOCUMENT-COUNT>2
<FILING-DATE>20051116
<DATE-OF-FILING-DATE-CHANGE>20051116
<SUBJECT-COMPANY>
<COMPANY-DATA>
<CONFORMED-NAME>ADVANCED NEUROMODULATION SYSTEMS INC
<CIK>0000351721
<ASSIGNED-SIC>3841
<IRS-NUMBER>751646002
<STATE-OF-INCORPORATION>TX
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>SC 14D9/A
<ACT>34
<FILE-NUMBER>005-33902
<FILM-NUMBER>051210580
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>6901 PRESTON RD.
<CITY>PLANO
<STATE>TX
<ZIP>75024
<PHONE>9723098000
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>6901 PRESTON RD.
<CITY>PLANO
<STATE>TX
<ZIP>75024
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>QUEST MEDICAL INC
<DATE-CHANGED>19920703
</FORMER-COMPANY>
</SUBJECT-COMPANY>
<FILED-BY>
<COMPANY-DATA>
<CONFORMED-NAME>ADVANCED NEUROMODULATION SYSTEMS INC
<CIK>0000351721
<ASSIGNED-SIC>3841
<IRS-NUMBER>751646002
<STATE-OF-INCORPORATION>TX
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>SC 14D9/A
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>6901 PRESTON RD.
<CITY>PLANO
<STATE>TX
<ZIP>75024
<PHONE>9723098000
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>6901 PRESTON RD.
<CITY>PLANO
<STATE>TX
<ZIP>75024
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>QUEST MEDICAL INC
<DATE-CHANGED>19920703
</FORMER-COMPANY>
</FILED-BY>
<DOCUMENT>
<TYPE>SC 14D9/A
<SEQUENCE>1
<FILENAME>a2164785zsc14d9a.htm
<DESCRIPTION>SC 14D9/A
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>

<P><FONT SIZE=2>
<hr noshade width=100% align=left size=4>
<hr noshade width=100% align=left size=1> </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=5><B>SECURITIES AND EXCHANGE COMMISSION<BR>  </B></FONT><FONT SIZE=2><B>WASHINGTON, D.C. 20549  </B></FONT></P>

<HR NOSHADE ALIGN="CENTER" WIDTH="120">
<P ALIGN="CENTER">


<FONT SIZE=5><B>SCHEDULE 14D-9<BR>
(RULE 14d-101)<BR>  </B></FONT><FONT SIZE=4><B>SOLICITATION/RECOMMENDATION STATEMENT<BR>
UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934<BR>
(Amendment No. 5)

  </B></FONT>

</P>

<HR NOSHADE ALIGN="CENTER" WIDTH="120">
<P ALIGN="CENTER"><FONT SIZE=4><B> Advanced Neuromodulation Systems,&nbsp;Inc.<BR>  </B></FONT><FONT SIZE=2>(Name of Subject Company) </FONT></P>

<HR NOSHADE ALIGN="CENTER" WIDTH="120">
<P ALIGN="CENTER"><FONT SIZE=4><B>Advanced Neuromodulation Systems,&nbsp;Inc.<BR>  </B></FONT><FONT SIZE=2>(Name of Person Filing Statement) </FONT></P>

<HR NOSHADE ALIGN="CENTER" WIDTH="120">
<P ALIGN="CENTER"><FONT SIZE=2><B>COMMON STOCK, PAR VALUE $.05 PER SHARE<BR>
(INCLUDING THE ASSOCIATED COMMON STOCK PURCHASE RIGHTS)<BR>  </B></FONT><FONT SIZE=2>(Title of Class of Securities) </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>00757T101<BR>  </B></FONT><FONT SIZE=2>(CUSIP Number of Class of Securities) </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>Christopher G. Chavez<BR>
President and Chief Executive Officer<BR>
Advanced Neuromodulation Systems,&nbsp;Inc.<BR>
6901 Preston Road<BR>
Plano, Texas 75024<BR>
(972)&nbsp;309-8000<BR>  </B></FONT><FONT SIZE=2>(Name, Address and Telephone Number of Person Authorized to<BR>
Receive Notice and Communications on Behalf of the Person(s) Filing Statement) </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>With
copies to each of: </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="49%" ALIGN="CENTER"><FONT SIZE=2><B>Kenneth G. Hawari<BR>
General Counsel and Executive Vice President<BR>
Advanced Neuromodulation Systems, Inc.<BR>
6901 Preston Road<BR>
Plano, Texas 75024-2508<BR>
(972) 309-8000</B></FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="49%" ALIGN="CENTER"><FONT SIZE=2><B>Joseph Cialone, II<BR>
Baker Botts L.L.P.<BR>
One Shell Plaza<BR>
910 Louisiana<BR>
Houston, TX 77002-4995<BR>
(713) 229-1234</B></FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2><FONT FACE="WINGDINGS">&#111;</FONT></FONT></DT><DD><FONT SIZE=2>Check
the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. </FONT></DD></DL>
<BR>

<P><FONT SIZE=2><hr
noshade width=100% align=left size=1>
<hr noshade width=100% align=left size=4> </FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2165220",CP="ADVANCED NEUROMODULATION SYSTEM",DN="1",CHK=280033,FOLIO='blank',FILE='DISK123:[05DFW1.05DFW1391]BA1391A.;6',USER='DCUSHIN',CD='16-NOV-2005;11:22' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P><FONT SIZE=2><A
NAME="page_ja1391_1_1"> </A> </FONT> <FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Amendment No.&nbsp;5 (this "Amendment") further amends and supplements the Solicitation/Recommendation Statement on Schedule&nbsp;14D-9, as amended through the date hereof (the
"Statement"), originally filed with the Securities and Exchange Commission on October&nbsp;19, 2005, by Advanced Neuromodulation Systems, Inc., a Texas corporation (the "Company"), relating to the
third-party tender offer by Apollo Merger Corp., a Texas corporation ("Purchaser" or "Apollo") and a wholly-owned subsidiary of St. Jude Medical, Inc., a Minnesota corporation ("Parent" or
"St.&nbsp;Jude Medical"), to purchase all of the issued and outstanding shares of common stock of the Company, par value $.05 per share (together with the associated rights issued pursuant to the
Rights Agreement dated August&nbsp;30, 1996 between Quest Medical, Inc. and KeyCorp Shareholder Services, Inc., as rights agent, as amended by the Amendment to Rights Agreement dated
January&nbsp;25, 2002 between the Company and Computershare Investor Services LLC and the Second Amendment to Rights Agreement dated October&nbsp;14, 2005 between the Company and Computershare
Investor Services LLC (as so amended, the "Rights Plan")) (the "Shares"), at a purchase price of $61.25 per share, net to the seller in cash, without interest thereon, upon the terms and subject to
the conditions set forth in the Offer to Purchase, dated October&nbsp;18, 2005 (the "Offer to Purchase") and in the related Letter of Transmittal (the "Letter of Transmittal") (which, together with
the Offer to Purchase and any amendments or supplements thereto, are referred to herein collectively as the "Offer"). The Offer to Purchase and the Letter of Transmittal are filed as
Exhibits&nbsp;(a)(2) and (a)(3) this Statement, respectively. Capitalized terms used and not otherwise defined in this Amendment shall have the meanings assigned to such terms in the Statement. The
purpose of this Amendment is to amend and supplement certain disclosure in the Statement and to attach a press release filed by St.&nbsp;Jude Medical on November&nbsp;16, 2005.

 </FONT></P>

<P>


<FONT SIZE=2><B>Item 8. Additional Information.


 </B></FONT>

</P>

<P>


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 8 of the Statement is hereby amended and supplemented by including the following at the end of the subsection entitled "Certain Other Matters":

</FONT>

</P>

<P>


<FONT SIZE=2><B><I>Subsequent Offering Period

  </I></B></FONT>

</P>

<P>


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At 12:00 midnight, New York City time, on Tuesday, November&nbsp;15, 2005, the Offer expired. Parent issued a press release announcing that Purchaser accepted
for purchase and payment in accordance with the terms of the Offer all Shares that were validly tendered as of the expiration of the Offer. According to Purchaser and Parent, approximately 15,769,679
Shares were validly tendered and not properly withdrawn as of the expiration of the Offer. Such tendered shares, together with approximately 2,257,821 Shares tendered subject to notices of guaranteed
delivery prior to the expiration of the Offer, represent approximately 89% of the outstanding Shares.

 </FONT>

</P>

<P><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On November&nbsp;16, 2005, Parent issued a press release announcing that Purchaser commenced a subsequent offering period in connection with the Offer, at 9:00&nbsp;a.m., New York
City time, on Wednesday, November&nbsp;16, 2005. The subsequent offering period will expire at 12:00 midnight, New York City time, on Friday, November&nbsp;18, 2005, unless extended. Purchaser and
Parent have advised the Company that Shares properly tendered during this subsequent offering period will be accepted as they are tendered and paid for promptly as they are accepted and that
shareholders who validly tender during this subsequent offering period will receive the same $61.25 per share cash consideration that is payable to shareholders who validly tendered during the initial
offering period. Purchaser and Parent have further advised the Company that procedures for tendering Shares during the subsequent offering period are the same as during the initial offering period,
with the exception that pursuant to Rule&nbsp;14d-7(a)(2) under the Securities Exchange Act of 1934, as amended, Shares tendered during the subsequent offering period may not be
withdrawn.

 </FONT></P>

<P><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A copy of the press release issued by Parent regarding the above is attached hereto as Exhibit&nbsp;(a)(5)(xiv), and the information in the press release is incorporated herein by
reference.

</FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2165220",CP="ADVANCED NEUROMODULATION SYSTEM",DN="1",CHK=520822,FOLIO='1',FILE='DISK123:[05DFW1.05DFW1391]JA1391A.;19',USER='JBAKER',CD='16-NOV-2005;15:20' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P><FONT SIZE=2><B>Item 9.&nbsp;&nbsp;&nbsp;&nbsp;Exhibits.  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following Exhibits are attached hereto: </FONT></P>




<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="78%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="12%" ALIGN="CENTER"><FONT SIZE=1><B>Exhibit Number</B></FONT><HR NOSHADE></TH>
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="86%" ALIGN="CENTER"><FONT SIZE=1><B>Description</B></FONT><HR NOSHADE></TH>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2>(a)(1)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2>Letter to the shareholders of the Company, dated October&nbsp;18, 2005.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(2)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Offer to Purchase, dated October&nbsp;18, 2005.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(3)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Form of Letter of Transmittal.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(4)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Opinion of Piper Jaffray &amp; Co., dated as of October&nbsp;14, 2005 (included as Annex A to this Statement).*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(5)(i)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Joint Press Release issued by the Company and St. Jude Medical on October&nbsp;16, 2005 (incorporated by reference to Exhibit&nbsp;99.1 of the Current Report on Form 8-K filed by the Company on October&nbsp;17, 2005).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(5)(ii)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Letter to employees of the subject company dated October&nbsp;17, 2005 with attached fact sheet (incorporated by reference to Exhibit&nbsp;99.1 of the pre-commencement Solicitation/Recommendation Statement on Form 14D-9 filed by the Company on
October&nbsp;17, 2005).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(5)(iii)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Employee Questions and Annswers, dated October&nbsp;17, 2005 (incorporated by reference to Exhibit&nbsp;99.2 of the pre-commencement Solicitation/Recommendation Statement on Form 14D-9 filed by the Company on October&nbsp;17, 2005).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(5)(iv)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Subject company fact sheet (incorporated by reference to Exhibit&nbsp;99.3 of the pre-commencement Solicitation/Recommendation Statement on Form 14D-9 filed by the Company on October&nbsp;17, 2005).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(5)(v)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Customer Letter, dated October&nbsp;17, 2005 (incorporated by reference to Exhibit&nbsp;99.4 of the pre-commencement Solicitation/Recommendation Statement on Form 14D-9 filed by the Company on October&nbsp;17, 2005).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(5)(vi)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Form of Clinical Studies Letter, dated October&nbsp;17, 2005 (incorporated by reference to Exhibit&nbsp;99.5 of the pre-commencement Solicitation/Recommendation Statement on Form 14D-9 filed by the Company on October&nbsp;17, 2005).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(5)(vii)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Form of Supplier Letter, dated October&nbsp;17, 2005 (incorporated by reference to Exhibit&nbsp;99.6 of the pre-commencement Solicitation/Recommendation Statement on Form 14D-9 filed by the Company on October&nbsp;17, 2005).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(5)(viii)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Form of letter to employees of the Company dated October&nbsp;19, 2005.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(5)(ix)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
International Customer Letter dated October&nbsp;27, 2005.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(5)(x)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Press Release issued by the Company on October&nbsp;27, 2005 (incorporated by reference to Exhibit&nbsp;99.1 of the Current Report on Form&nbsp;8-K filed by the Company on October&nbsp;27, 2005).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(5)(xi)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Employee Questions and Answers, Part II, dated October 27, 2005.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(5)(xii)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Press Release issued by St.&nbsp;Jude Medical on November&nbsp;4, 2005.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(5)(xiii)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Press Release issued by St.&nbsp;Jude Medical on November&nbsp;11, 2005.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(5)(xiv)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Press Release issued by St.&nbsp;Jude Medical on November&nbsp;16, 2005.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(6)(i)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Part 13 of the Texas Business Corporation Act.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(a)(6)(ii)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Articles 5.11, 5.12, 5.13 and 5.16(E) of the Texas Business Corporation Act.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE>

<!-- insert table folio -->
<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2165220",CP="ADVANCED NEUROMODULATION SYSTEM",DN="1",CHK=860133,FOLIO='blank',FILE='DISK123:[05DFW1.05DFW1391]JE1391A.;11',USER='DCUSHIN',CD='16-NOV-2005;11:27' -->
<!-- end of table folio -->


<TABLE WIDTH="78%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(e)(1)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Agreement and Plan of Merger, dated as of October&nbsp;15, 2005, among St. Jude Medical, the Purchaser and the Company (incorporated by reference to Exhibit&nbsp;2.1 to the Form 8-K filed by the Company on October&nbsp;17, 2005).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(e)(2)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Information Statement of the Company, dated October&nbsp;18, 2005 (included as Annex B hereto).*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(e)(3)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Confidentiality Agreement dated July 28, 2005 between the Company and St. Jude Medical.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(e)(4)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Special Termination Agreement between the Company and Christopher G. Chavez, President and Chief Executive Officer, dated as of April&nbsp;1, 2002.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(e)(5)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Special Termination Agreement between the Company and Mr.&nbsp;Kenneth G. Hawari, General Counsel, Executive Vice President&#151;Corporate Development and Secretary, dated as of April 1, 2002.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(e)(6)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Special Termination Agreement between the Company and Mr.&nbsp;Scott F. Drees, Executive Vice President&#151;Operations, dated as of May 25, 2001.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(e)(7)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Special Termination Agreement between the Company and Mr.&nbsp;F. Robert Merrill, III, Chief Financial Officer, dated as of May&nbsp;25, 2001.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(e)(8)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Special Termination Agreement between the Company and Mr.&nbsp;James P. Calhoun, Vice President&#151;Human Resources, dated as of May&nbsp;25, 2001.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(e)(9)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Special Termination Agreement between the Company and Mr.&nbsp;John H. Erickson, Vice President&#151;Research &amp; Development, dated as of May&nbsp;25, 2001.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(e)(10)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Special Termination Agreement between the Company and Mr.&nbsp;Stuart B. Johnson, Vice President&#151;Manufacturing, dated as of May 25, 2001.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(e)(11)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Second Amendment to Rights Agreement, dated as of October&nbsp;14, 2005.*</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
(g)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="86%"><FONT SIZE=2><BR>
Not applicable.</FONT></TD>
</TR>
</TABLE>


<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE ALIGN="LEFT" WIDTH="120">
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD><FONT SIZE=2>Previously
filed. </FONT></DD></DL>
<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=4,EFW="2165220",CP="ADVANCED NEUROMODULATION SYSTEM",DN="1",CHK=398697,FOLIO='blank',FILE='DISK123:[05DFW1.05DFW1391]JE1391A.;11',USER='DCUSHIN',CD='16-NOV-2005;11:27' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- SEQ=,FILE='QUICKLINK',USER=JBAKER,SEQ=,EFW="2165220",CP="ADVANCED NEUROMODULATION SYSTEM",DN="1" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.(A)(5)(XIV)
<SEQUENCE>2
<FILENAME>a2165220zex-99_a5xiv.htm
<DESCRIPTION>EXHIBIT 99.(A)(5)(XIV)
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="page_nr1391_1_1"> </A> </FONT> <FONT SIZE=2><B>Exhibit (a)(5)(xiv)  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT> <FONT SIZE=6>News Release... </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="10%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="28%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="28%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="28%"><FONT SIZE=1>St. Jude Medical<BR>
One Lillehei Plaza<BR>
St. Paul, Minnesota 55117<BR>
(651) 483.2000<BR>
www.sjm.com</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="10%"><FONT SIZE=2><B>Contacts</B></FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="28%"><FONT SIZE=2>Laura Merriam<BR>
Investor Relations<BR>
(651) 766-3029</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="28%"><FONT SIZE=2>Angela Craig<BR>
Media Relations<BR>
(651) 481-7789</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="28%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2><B>St. Jude Medical Acquires Approximately 89% Of<BR>
Advanced Neuromodulation Systems; Announces Subsequent Offering Period  </B></FONT></P>

<P><FONT SIZE=2>ST. PAUL, MN, November&nbsp;16, 2005&#151;St. Jude Medical,&nbsp;Inc. (NYSE:STJ) announced today that the tender offer for all of the outstanding shares of common
stock of Advanced Neuromodulation Systems,&nbsp;Inc. (NASDAQ:ANSI) expired at midnight, Eastern Time, Tuesday, November&nbsp;15, 2005. St. Jude Medical has accepted for purchase and payment all of
the shares that were validly tendered as of the expiration of the offer. The preliminary results of the offer show that approximately 15,769,679 shares of ANS common stock were validly tendered and
not properly withdrawn as of the expiration date, satisfying the minimum condition for the tender offer. Such tendered shares, together with approximately 2,257,821 shares subject to notices of
guaranteed delivery (for a total of approximately 18,027,500 ANS shares), represent approximately 89% of ANS's outstanding shares. </FONT></P>

<P><FONT SIZE=2>As
described in the Offer to Purchase, St. Jude Medical and ANS are providing for a subsequent offering period which begins today at 9:00&nbsp;a.m., Eastern Time, and expires at midnight, Eastern
Time, on Friday, November&nbsp;18, 2005. During this subsequent offering period, shares of ANS common stock will be accepted and promptly paid for as they are tendered. The same per share
consideration paid during the initial offering period, $61.25 net per share in cash, will be paid during the subsequent offering period. Shares of ANS common stock tendered during the subsequent
offering period may not be withdrawn. </FONT></P>

<P><FONT SIZE=2>MacKenzie
Partners,&nbsp;Inc. is acting as information agent in connection with the tender offer and can be contacted at (800)&nbsp;322-2885 (toll free) or
(212)&nbsp;929-5500 (collect). The Dealer Manager for the tender offer is Banc of America Securities LLC. </FONT></P>

<P><FONT SIZE=2><B>About St. Jude Medical</B></FONT><FONT SIZE=2><BR>
St. Jude Medical,&nbsp;Inc. (<U>www.sjm.com</U>) is dedicated to the design, manufacture and distribution of innovative medical devices of the highest quality, offering
physicians, patients and payers outstanding clinical performance and demonstrated economic value. </FONT></P>


<P><FONT SIZE=2><B>About ANS</B></FONT><FONT SIZE=2><BR>
ANS (<U>www.ANS-medical.com</U>) designs, develops, manufacturers and markets implantable systems used to manage chronic intractable pain and other disorders of the
central nervous system. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2165220",CP="ADVANCED NEUROMODULATION SYSTEM",DN="2",CHK=161108,FOLIO='1',FILE='DISK123:[05DFW1.05DFW1391]NR1391A.;2',USER='DCUSHIN',CD='16-NOV-2005;11:25' -->
<A NAME="page_nr1391_1_2"> </A>
<BR>

<P><FONT SIZE=2><B>Forward-Looking Statements<BR>  </B></FONT><FONT SIZE=2><I>Any statements made regarding the proposed transaction between St. Jude Medical,&nbsp;Inc. and Advanced Neuromodulation Systems,&nbsp;Inc., the expected timetable for
completing the transaction, successful integration of the business, benefits of the transaction, potential clinical success, regulatory approvals, anticipated future product launches, revenues,
earnings, expected repayment of debt, market shares, market growth, market segment growth, new indications, and any other statements regarding St. Jude Medical's or ANS's future expectations, beliefs,
goals or prospects are forward-looking statements which are subject to risks and uncertainties, such as those described under or incorporated by reference in the Cautionary Statements section in Item
2 of St. Jude Medical's Quarterly Report on Form&nbsp;10-Q filed on November&nbsp;8, 2005 (see page 35), and in Item 8.01 of ANS's Current Report on Form&nbsp;8-K filed
on October&nbsp;17, 2005, and in the Outlook and Uncertainties section in ANS's Quarterly Report on Form&nbsp;10-Q for the quarter ended September&nbsp;30, 2005 (see page 26), and
ANS's Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2004 (see page 26). Actual results may differ materially from anticipated results.</I></FONT></P>

<P><FONT SIZE=2><B>Additional Information<BR>  </B></FONT><FONT SIZE=2><I>This announcement is neither an offer to purchase nor a solicitation of an offer to sell shares of ANS. St. Jude Medical has filed a tender offer statement with the Securities
and Exchange Commission (SEC) and ANS has filed a solicitation/recommendation statement with respect to the offer. ANS shareholders are advised to read the tender offer statement regarding the
acquisition of ANS referenced in this news release, and the related solicitation/recommendation statement. The tender offer statement and the solicitation/recommendation statement contain important
information that should be read carefully before any decision is made with respect the offer. These documents are available at no charge on the SEC's web site at www.sec.gov. Shareholders may also
obtain copies of these documents without charge by requesting them from MacKenzie Partners,&nbsp;Inc., (800)&nbsp;322-2885 (toll free) or (212)&nbsp;929-5500 (collect),
the Information Agent for the tender offer.</I></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=2,EFW="2165220",CP="ADVANCED NEUROMODULATION SYSTEM",DN="2",CHK=375353,FOLIO='2',FILE='DISK123:[05DFW1.05DFW1391]NR1391A.;2',USER='DCUSHIN',CD='16-NOV-2005;11:25' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- SEQ=,FILE='QUICKLINK',USER=JBAKER,SEQ=,EFW="2165220",CP="ADVANCED NEUROMODULATION SYSTEM",DN="2" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SUBMISSION>
